Encephalitis Clinical Trial
Official title:
Pharmacokinetic Study of AVI-4065 in Cerebral Spinal Fluid Among Healthy Adult Males Following Subcutaneous Administration
AVI-4020 Injection, a phosphorodiamidate Morpholino oligomer (PMO), was found to cross the blood-brain barrier during a study of patients with presumptive West Nile virus disease. AVI-4065, which was designed to target HCV, is also a PMO; its ability to cross the blood-brain barrier is unknown. In this study, a single dose of AVI-4065 will be subcutaneously injected, and samples collected to determine if this drug crosses the blood-brain barrier. If it does, then additional investigations could be performed in people with severe forms of HCV disease in which the brain is affected.
AVI-4020 Injection, a phosphorodiamidate Morpholino oligomer (PMO), was found to cross the
blood-brain barrier during a study of patients with presumptive West Nile virus disease.
AVI-4065, which was designed to target HCV, is also a PMO; its ability to cross the
blood-brain barrier is unknown. As the incidence of HCV disease has grown, the knowledge
base of this disease has likewise increased.
Encephalopathy is a recognized consequence in some patients with HCV infection. In this
study, a single dose of AVI-4065 will be subcutaneously injected, and samples collected to
determine if this drug crosses the blood-brain barrier. If it does, then additional
investigations could be performed in people with HCV disease in which the brain is affected.
;
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02538094 -
tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis
|
N/A | |
| Completed |
NCT00031486 -
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
|
Phase 3 | |
| Completed |
NCT00069303 -
Natural History of West Nile Virus Infection
|
N/A | |
| Completed |
NCT02906631 -
Epidemiology and Prognosis of Encephalitis in Intensive Care
|
||
| Completed |
NCT02367664 -
A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants
|
Phase 3 | |
| Completed |
NCT00314132 -
Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.
|
Phase 3 | |
| Terminated |
NCT00927953 -
Treatment of West Nile Virus With MGAWN1
|
Phase 2 | |
| Recruiting |
NCT05393492 -
Regulating Emotions and Behaviors After Brain Injury
|
N/A | |
| Terminated |
NCT04361344 -
Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection
|
N/A | |
| Recruiting |
NCT04460599 -
Neurological Features During COVID19
|
||
| Recruiting |
NCT04372615 -
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
|
Phase 2 | |
| Completed |
NCT02714959 -
IL-2 in Refractory Autoimmune Encephalitis
|
Phase 1/Phase 2 | |
| Completed |
NCT01092507 -
A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers
|
Phase 3 | |
| Completed |
NCT01041573 -
Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population
|
Phase 3 | |
| Not yet recruiting |
NCT04722328 -
Establishment of Prevention and Control System of Central Nervous System Infection
|
||
| Recruiting |
NCT06067750 -
Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
|
||
| Not yet recruiting |
NCT06368648 -
CoMind Early Feasibility Study
|
||
| Completed |
NCT02526550 -
Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX
|
Phase 4 | |
| Completed |
NCT01694524 -
Nervous System Infections Among Patients With Febrile Seizure
|
N/A | |
| Completed |
NCT04080921 -
Stem Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis
|
Phase 1/Phase 2 |